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Identification of a seven glycopeptide signature
for malignant pleural mesothelioma in human
serum by selected reaction monitoring
Ferdinando Cerciello1,2*, Meena Choi3, Annalisa Nicastri4, Damaris Bausch-Fluck1,5,8, Annemarie Ziegler2,9,
Olga Vitek3,6, Emanuela Felley-Bosco2, Rolf Stahel2, Ruedi Aebersold1,7 and Bernd Wollscheid1,5,8*
Abstract
Background: Serum biomarkers can improve diagnosis and treatment of malignant pleural mesothelioma (MPM).
However, the evaluation of potential new serum biomarker candidates is hampered by a lack of assay technologies
for their clinical evaluation. Here we followed a hypothesis-driven targeted proteomics strategy for the identification
and clinical evaluation of MPM candidate biomarkers in serum of patient cohorts.
Results: Based on the hypothesis that cell surface exposed glycoproteins are prone to be released from tumor-cells
to the circulatory system, we screened the surfaceome of model cell lines for potential MPM candidate biomarkers.
Selected Reaction Monitoring (SRM) assay technology allowed for the direct evaluation of the newly identified
candidates in serum. Our evaluation of 51 candidate biomarkers in the context of a training and an independent
validation set revealed a reproducible glycopeptide signature of MPM in serum which complemented the MPM
biomarker mesothelin.
Conclusions: Our study shows that SRM assay technology enables the direct clinical evaluation of protein-derived
candidate biomarker panels for which clinically reliable ELISA’s currently do not exist.
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Serum biomarkers
Background
Malignant pleural mesothelioma (MPM) is a fatal cancer
of the pleura induced by asbestos exposure. Treatments
developed over the last decade have improved patient
survival [1-5]. However, their efficacy is limited by the
frequent detection of MPM only at advanced stages
[6,7]. Easily and longitudinally accessible blood biomarkers
are expected to support diagnosis and therapy selection
at early disease stages, when benefit from treatment is the
highest [8]. To date, the best available MPM biomarker
in serum is mesothelin [9]. While the protein is frequently
elevated at advanced stages of the disease, its value for
early detection remains limited [10]. The search and
evaluation of additional MPM biomarkers in serum
remains thus a priority. Generally, this is approached
applying enzyme linked immunosorbent assays (ELISA),
which commonly allow for the reliable evaluation of only
one biomarker candidate at the time, like in the case of
the recently proposed fibulin-3 protein [11]. An alternative
would be the investigation of panels of simultaneously
measured biomarkers. Such a multiplexed strategy
would be a more efficient approach in terms of samples
consumption and diagnostic accuracy [12]. To achieve
this goal, in our study we developed and applied a
hypothesis-driven targeted proteomics strategy which
enabled the parallel quantitative evaluation of potential
MPM candidate biomarkers in serum through SRM
assay technology.
SRM assay technology relies on the ability of a triple-
quadrupole mass spectrometer (QQQ) to selectively
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isolate predefined peptides of interest in a complex protein
mixture after enzymatic digestion (usually using trypsin)
[13]. SRM-assays encompass the analytical coordinates ne-
cessary for the unambiguous detection and quantification
of the target candidates [14]. They consist of selected
peptide-transitions to monitor (the pairs of signals repre-
senting the precursor peptide-ion and a corresponding
fragment-ion), best collision energies to apply for peptide-
fragmentations in the mass spectrometer and retention
times of the target peptides in a chromatographic separ-
ation column. In a single SRM analysis, dozens of peptides
are simultaneously quantified in complex samples with
high sensitivity and reproducibility as surrogates of their
proteins [15]. This multiplexing potential enables parallel
testing and clinical evaluation of proposed candidate bio-
markers in clinically relevant specimens [16,17].
In our study, to identify new candidate biomarkers
for MPM we performed quantitative discovery-driven
screening of the surfaceome of MPM model cell lines.
This has previously been proposed as a valuable source
of MPM candidate biomarkers [18]. Subsequently, we
used SRM assay technology to clinically evaluate the
surfaceome-derived MPM candidate biomarkers in serum
samples of suitably collected cohorts of MPM subjects
and controls (Figure 1A and B).
Results
Quantitative analysis of mesothelin in serum
To verify the SRM based approach for MPM biomarkers
in serum, we performed quantitative investigations of
mesothelin in samples enriched for N-linked glycopeptides
(N-glycopeptides). This enrichment step was chosen in
our study to efficiently and reproducibly reduce the
analytical complexity of the serum proteome and to
focus our investigation on a sub-proteome particularly
relevant for biomarker research, like represented by the
N-linked glycoproteins (N-glycoproteins) [19-23]. To
generate and optimize SRM-assays for the quantitative
analysis of mesothelin, we followed the strategy proposed
by Picotti et al. [24] using spectral libraries from
chemically synthesized peptide-sequences. We established
SRM-assays for the N-glycopeptides of membrane-bound
mesothelin [25] (Additional file 1: Table S1) which is
shed in serum [26,27] and for which a commercial ELISA-
kit approved by the US Food and Drug Administration
(FDA) (MesomarkW) [28,29] is available. We selected
quantitative SRM-assays based on the N-glycopeptide
KWDVTSLETLK (UniProt/Swiss-Prot: Q13421; D replaces
the formerly glycosylated N after deamidation with the
enzyme PNGaseF in the protocol for N-glycopeptide
enrichment in serum [21]) which was routinely observed
in our experiments (Additional file 2: Figure S1). We
then quantified mesothelin using SRM assay technology
in enriched serum samples from 75 subjects (23 MPM,
26 healthy donors, HD, and 26 non-small cell lung
cancer, NSCLC, Additional file 3: Table S2). In parallel,
in the same subjects we performed mesothelin quantifi-
cation based on the FDA approved ELISA (Additional
file 3: Table S2). The results showed firstly, a significant
correlation between the quantification of mesothelin
assessed by SRM at the glycopeptide level and by ELISA
at the protein level (Figure 2A). Furthermore, differences
in mean concentrations of mesothelin measured by ELISA
among the groups of MPM, HD and NSCLC were
reflected by SRM assay technology (Figure 2B). These
results provided evidence for the ability of the SRM based
approach in serum to accurately identify and quantify
MPM biomarkers of clinical relevance.
Surfaceome derived serum candidate biomarkers for
malignant pleural mesothelioma
To identify candidate biomarkers for MPM, we performed
a quantitative discovery-driven surfaceome screening in
cell lines. To do so, we applied the mass spectrometry
(MS) based Cell Surface Capture (CSC) technology [30]
in two epithelioid and two biphasic MPM cell lines
in parallel with two NSCLC (lung adenocarcinoma)
and two non-cancerous pleural cell lines. A total of
668 N-glycopeptides were confidently (PeptideProphet
probability ≥ 0.9) detected from more than 350 N-gly-
coproteins, which could potentially be shed into the
blood stream. 514 N-glycopeptides were from MPM
and 557 from non-MPM cell lines with 403 N-glycopep-
tides in common between the two groups. We prioritized
candidate biomarkers potentially specific for MPM by
focusing on N-glycopeptides reproducibly detected in
higher abundance or in strong association with MPM
cell lines. This screen led to the selection of 125 N-gly-
copeptides candidate biomarkers for MPM (Additional
file 4: Table S3).
Subsequently, we applied SRM assay technology for
the multiplexed assessment of these candidate biomarkers
in serum. To generate SRM-assays for the candidate
biomarkers, we used again spectral libraries from
chemically synthesized peptide-sequences and acquired
spectra without confounding background matrices. The
strategy enabled us to avoid potential MS platform related
transition-selection biases [31] and sufficient peptide
amounts for establishing optimized SRM-assays [24].
We obtained fragment spectra suitable for the library
from 112 out of the initial 125 MPM candidate biomarkers
and for these peptides we established initial SRM-assays
in the background matrix of serum samples enriched
for N-glycopeptides. We then performed multiplexed
verification of the in serum unknown detectability of
these candidate biomarkers by analyzing enriched serum
samples of five MPM subjects (Additional file 5: Skyline
file). In this initial screen we detected a total of 51 N-
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glycopeptides belonging to 36 N-glycoproteins which in
the literature are reported at concentrations in serum/
plasma between 180 μg/ml (hemopexin, UniProt/Swiss-
Prot: P02790, peptide SWPAVGNCSSALR) and 0.92 ng/
ml (poliovirus receptor-related protein 1, UniProt/Swiss-
Prot: Q15223, peptide NPNGTVTVISR) (Additional file
6: Figure S2 and Additional file 7: Table S4) [32]. The
majority of these proteins are reported at concentrations
below 100 ng/ml and thus in the range of MPM bio-
markers previously proposed in the literature [11,33,34]
(Figure 3). Taken together, these observations supported
the suitability and sensitivity of our targeted SRM-based
approach for MPM biomarker investigation in serum.
Seven glycopeptide signature for malignant pleural
mesothelioma
To assess the diagnostic potential of the 51 MPM can-
didate biomarkers, we relatively quantified them via
optimized SRM-assays in an initial set of enriched
serum samples from clinical cohorts of MPM (N= 25),
HD (N= 25) and NSCLC subjects (N = 25) (clinical charac-
teristics are reported in Additional file 8: Table S5). We
used these samples as the training set for a predictive ana-
lysis. SRM assay technology allowed us to quantify all
51 MPM candidate biomarkers in parallel in one single
injection per sample (Additional file 9: Table S6). Stat-
istical significance analysis [37] identified four N-
glycopeptides significantly higher in abundance in MPM
as compared to HD and six N-glycopeptides of higher
abundance in MPM as compared to NSCLC (Additional
file 7: Table S4). We selected these ten peptides as
candidate predictors in two separate logistic regression
models for binary responses between MPM and HD or
MPM and NSCLC. We than performed a stepwise se-
lection of predictors and evaluation of their predictive
ability using receiver operating characteristic (ROC)
Figure 1 Workflow of the study. (A) MPM candidate biomarker glycopeptides were identified from the surfaceome of model cell lines (1).
Detection in serum was targeted verified by SRM assay technology (2). Diagnostic significance was investigated by multiplexed SRM assay
technology in clinical cohorts (3). (B) CSC technology was applied for the quantitative surfaceome screening of four MPM, two non-cancerous
pleural and two NSCLC (lung adenocarcinoma) cell lines for MPM candidate biomarker N-glycopeptides (Additional file 4: Table S3) (1). SRM-assays
were generated for the MPM candidate biomarkers and applied for the screening of five MPM sera (Additional file 7: Table S4 and Additional
file 5: Skyline file) (2). SRM-assays for MPM candidate biomarkers detected in serum were multiplexed in one single SRM-method and quantitatively
evaluated in a clinical training set of enriched sera from 25 MPM, 25 HD and 25 NSCLC (Additional file 8: Table S5 and Additional file 9: Table S6) (3).
Candidate biomarkers detected at higher abundance in sera of MPM were combined in logistic regression models to derive a multiplexed
panel of six glycopeptides with optimal accuracy in discriminating MPM from HD. The panel was further confirmed in an independent
validation set of 30 MPM, 29 HD and 28 NSCLC (Additional file 8: Table S5) together with the SRM-based monitoring of the biomarker mesothelin
(Additional file 11: Table S7).
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curves to identify a multiplexed panel of MPM candi-
date biomarkers with best discriminatory performance
for MPM. The panel was composed by the six glyco-
peptides derived from the N-glycoproteins intercellular
adhesion molecule 1 (UniProt/Swiss-Prot: P05362, peptide
sequence ADLTVVLLR), basement membrane-specific
heparan sulfate proteoglycan core protein (P98160,
ALVDFTR), anthrax toxin receptor 1 (Q9H6X2, DFDETQ-
LAR), serum paraoxonase/arylesterase 1 (P27169, HA
DWTLTPLK), hypoxia up-regulated protein 1 (Q9Y
4L1, VIDETWAWK) and thrombospondin-1 (P07996,
VVDSTTGPGEHLR). In the training set, the panel dis-
criminated MPM from HD with an area under the
curve (AUC) of 0.94 (95% confidence interval, CI,
[0.87, 0.99]) and the highest accuracy (highest true pos-
itives and true negatives) of 90% (95% CI, [82, 100]) at
a cut-off of 0.61 (Figure 4A). Subsequently, we confirmed
the performance of the six glycopeptide panel in an
independent validation set of 87 sera newly enriched for
N-glycopeptides from MPM (N= 30), HD (N= 29) and
NSCLC (N = 28) subjects (Additional file 8: Table S5).
Here the panel discriminated MPM from HD with AUC
of 0.94 (95% CI, [0.86, 0.99]) and accuracy of 86% (95% CI,
[78, 95]) at the 0.61 cut-off (Figure 4B). However, the
panel failed to discriminate MPM from NSCLC: AUC
in the training set was 0.77 (95% CI, [0.62, 0.91]) with
accuracy of 74% (cut-off 0.35; 95% CI, [62, 88]) (Figure 4C)
and in the validation set was 0.56 (95% CI, [0.40, 0.71])
with accuracy of 59% (cut-off 0.35; 95% CI, [50, 88])
(Figure 4D).
We compared the discriminatory performance of the six
glycopeptides panel to that of the FDA approved ELISA
assay for mesothelin (MesomarkW) [28] (Additional file 10:
Figure S3). In the 75 subjects above (23 MPM, 26 HD
and 26 NSCLC, Additional file 3: Table S2) for which
ELISA measurements were available, mesothelin ELISA
discriminated MPM from HD with AUC of 0.92 (95%
CI, [0.83, 0.99]) and accuracy of 82% (95% CI, [71, 94])
at the 2 nM cut-off proposed in the literature [10]. In
the same subjects, which were part of the validation set
Figure 2 Quantification of serum mesothelin. (A) Correlation between the quantification of serum mesothelin by SRM assay technology
(peptide KWDVTSLETLK) or by ELISA (MesomarkW) among 75 subjects (23 MPM = red dots, 26 HD = blue dots, 26 NSCLC = green dots) (Additional
file 3: Table S2). Reported is the Spearman’s rank correlation coefficient (P < 0.05 is considered significant). Dashed line denotes best fit as
calculated by linear regression (y = 8.1 + 0.82x). (B) Serum levels of mesothelin assessed by ELISA (Mesomark®) or by SRM assay technology
(peptide KWDVTSLETLK) in the groups of MPM, HD and NSCLC of the 75 subjects (23 MPM, 26 HD, 26 NSCLC) (Additional file 3: Table S2).
Significant differences of mean levels between the groups are assessed using the Mann-Whithney test. P-values are two-tailed and considered
significant if < 0.05. Boxes report 25th and 75th percentile. Crosses inside the boxes indicate means and lines indicate medians. Whiskers indicate
minimal and maximal values.
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above, the six glycopeptides panel based on SRM assay
technology had AUC of 0.94 (95% CI, [0.86, 0.99]) and
accuracy of 86% (95% CI, [71, 96]) at the 0.61 cut-off,
indicating a discriminatory power similar to that of the
ELISA assay. For the discrimination between MPM and
NSCLC, mesothelin ELISA was superior to SRM and had
AUC of 0.84 (95% CI, [0.71, 0.94]) whereas the six glyco-
peptides panel had AUC of 0.54 (95% CI, [0.37, 0.71]).
From this last observation, we argued that the specificity
of the SRM panel for MPM could be increased by in-
cluding mesothelin. Thus, we added the SRM monitoring
of mesothelin peptide KWDVTSLETLK to the signature
(Table 1 and Additional file 11: Table S7) and tested it
in the group of 75 subjects for which mesothelin ELISA
measurements were available for comparison. We per-
formed parameterization of the signature using a sub-
training set of 12 MPM, 14 HD and 14 NSCLC and
assessed its performance in a sub-validation set of 11
MPM, 12 HD and 12 NSCLC (Figures 5A and B). Here,
the SRM based signature discriminated MPM from HD
with AUC of 0.95 (95% CI, [0.83, 1.0]) and highest
accuracy of 91% (95% CI, [83, 100]) and MPM from
NSCLC with AUC of 0.84 (95%CI, [0.66, 0.97]) and high-
est accuracy of 74% (95% CI, [57, 91]). The performance
of the signature was higher than for mesothelin ELISA,
which in the same subjects had AUC of 0.93 (95% CI,
[0.84, 1.0]) and accuracy of 78% (95% CI, [61, 96]; cut-off
2 nM) in discriminating MPM from HD and AUC of 0.80
(95% CI, [0.59, 0.95]) and accuracy of 74% (95% CI, [57,
100]; cut-off 2 nM) in discriminating MPM from NSCLC.
Discussion
The development of protein biomarkers in serum requires
the availability of reliable analytical tools for the unbiased
prioritization and large scale clinical testing of novel
candidates [38,39]. ELISA’s assays for biomarker inves-
tigation are typically obtainable only for a subset of
candidates and establishing new ELISA’s solely for the
purpose of testing candidates is time consuming and
too expensive [40,41]. In our study, we presented the
application of targeted proteomics SRM assay technology
in serum for the investigation and clinical evaluation of
candidate biomarker panels for MPM. The approach
presented itself as an accurate alternative to immunoassays
and allowed us to follow a hypothesis driven biomarker
investigation independently of the still piecemeal avail-
ability of antibodies.
The underlying hypothesis of our investigation was that
the surfaceome of MPM can reveal novel blood accessible
biomarkers. This was suggested by the fact that the cell
surface proteins are exposed to the tumor environment
and thus prone to be shed or released to the stroma
and finally collected into the blood [42,43]. Indeed,
many proposed blood tumor-markers like mesothelin,
Figure 3 Concentration ranges of proteins originating MPM candidate biomarker peptides detected through SRM-assays in serum.
Reported are protein concentrations in serum/plasma available from the PeptideAtlas database [32] (red dots) (Additional file 7: Table S4). For
comparison, cut-off levels of selected MPM biomarkers in serum/plasma proposed by the literature [11,33-36] are reported (blue dots). Concentrations
are reported in logarithmic scale.
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carcinoembryonic antigen (CEA) or cancer antigen 125
(CA-125) are glycoproteins of cell surface origin. Following
this hypothesis, our SRM investigation in serum detected
51 out of the 112 surfaceome derived candidate biomarkers.
This was a considerable fraction of the candidates,
considering that they were selected without prior
knowledge and from extremely simplified tumor models
as represented by cell lines. Interestingly, the majority
of the candidates were at concentrations in the
range of proposed MPM biomarkers like fibulin-3,
Table 1 Seven glycopeptide signature for MPM in serum
MPM candidate biomarker N-glycopeptides
monitored by SRM*
Protein name UniProt/Swiss-Prot entry Gene name ng/ml**
ADLTVVLLR Intercellular adhesion molecule 1 P05362 ICAM1 71
ALVDFTR Basement membrane-specific heparan
sulfate proteoglycan core protein
P98160 HSPG2 120
DFDETQLAR Anthrax toxin receptor 1 Q9H6X2 ANTXR1 Not available
HADWTLTPLK Serum paraoxonase/arylesterase 1 P27169 PON1 22'000
VIDETWAWK Hypoxia up-regulated protein 1 Q9Y4L1 HYOU1 6.6
VVDSTTGPGEHLR Thrombospondin-1 P07996 THBS1 510
KWDVTSLETLK Mesothelin Q13446 MSLN Not available
*D replaces the former glycosylated N in the natural peptide sequence after deamidation induced by PNGaseF treatment.
**Concentration in serum/plasma as estimated in PeptideAtlas (ref. Farrah et al. [32]).
Figure 4 ROC curves of the six glycopeptides panel. Discrimination between MPM and HD (A, B) and MPM and NSCLC (C, D) in training
(A, C) and validation (B, D) sets. Accuracies for MPM vs HD are at cut-off 0.61 and for MPM vs NSCLC at 0.35.
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megakaryocyte potentiating factor (MPF) or osteopon-
tin. This observation, together with the SRM detection of
mesothelin, confirmed that our targeted proteomics strat-
egy could reliably access that fraction of the serum prote-
ome which seems to be of particular relevance for MPM
biomarker investigations.
In our study, if available, at least two surfaceome de-
tected N-glycopeptides per protein were initially inves-
tigated by SRM in serum. For our final MPM signature
in serum we selected the best peptide for a particular
protein, e.g. these peptides were most consistently detected.
Potential variations in the detectability and response factor
of peptides from the same proteins are related to a number
of reasons. One reason is certainly related to the fact
that each peptide has its peculiar physicochemical char-
acteristics which will influence its mass spectrometric
detection independently of a common protein of origin
[44,45]. At the same time it is also likely that the signature
reflects the complexity of a natural tissue environment
[46,47]. Indeed, several biochemical and proteolytic
processes are expected to take place in the tumor
microenvironment which can modify the original
structure of the cell surface proteins [48,49]. It is thus
likely that not intact proteins but rather only fragments of
them will reach and pass the vessel barriers [50,51]. This
could at least in part explain the apparently asynchronous
behavior in serum of peptides from the same protein.
Despite the confident discrimination between MPM
and healthy, our study cannot conclusively answer the
question if the candidate biomarkers of the signature are
MPM specific or rather more generally cancer associated.
Indeed, without mesothelin, the six biomarkers of the
signature failed to discriminate MPM from NSCLC and
their association with other tumors is reported [52-56].
Nevertheless, the SRM signature inclusive of mesothelin
presented accuracies higher than the ELISA test for the
single marker mesothelin. This indicated that the integra-
tion of the seven MPM biomarkers in the multiplexed
SRM signature could complement the limited sensitivity
of mesothelin, taking at the same time advantage of its
specificity for MPM. Here, we have to point out that,
because of the exploratory nature of our investigation,
the majority of the patients included in our study were at
advanced disease stages and that controls did not include
confounding conditions like chronic inflammations or
other non-malignant pathologies of the lung. As a con-
sequence, the accuracy of the MPM signature could be
lower if applied to more heterogeneous populations, like
indirectly suggested by the higher AUCs of mesothelin
ELISA of our study in respect to literature reports [10].
Finally, it has to be highlighted that the MPM signa-
ture includes hypoxia up-regulated protein 1 (also
known as ORP150 or GRP170; UniProt/Swiss-Prot:
Q9Y4L1, gene name HYOU1) which is a heat shock
protein with chaperone function in the endoplasmic
reticulum [57]. This could arise some concern about
the specificity of our approach. It is therefore worth-
while to mention here that, in accord with other groups
[58,59], in our surfaceome experiments we reproducibly
observed the protein and it is known that heat shock
proteins can be expressed on cell surfaces or be se-
creted to blood [60-63].
Figure 5 ROC curves of the seven glycopeptide MPM signature. Discrimination between MPM and HD (A) and MPM and NSCLC (B) using
the SRM-based seven glycopeptide signature or using mesothelin ELISA. Parameterization of the seven glycopeptide signature was performed in
a sub-training set (12 MPM, 14 HD and 14 NSCLC) and applied to a sub-validation set (11 MPM, 12 HD and 12 NSCLC) of the group of 75 subjects
for which mesothelin ELISA (Mesomark®) measurements were available. Reported are AUCs for the seven glycopeptide signature (blue line) and
mesothelin ELISA (red line) in the sub-validation set. Accuracy of the seven glycopeptide signature is at cut-off 0.5 for MPM vs HD and 0.6 for
MPM vs NSCLC. Accuracy for mesothelin ELISA is at 2 nM cut-off. CI indicates a 95% confidence interval.
Cerciello et al. Clinical Proteomics 2013, 10:16 Page 7 of 12
http://www.clinicalproteomicsjournal.com/content/10/1/16
Conclusions
In conclusion, the SRM assay technology based approach
chosen for our clinical MPM investigation allowed us
to directly evaluate a larger set of candidate serum bio-
markers resulting in a seven glycopeptide signature
with diagnostic potential for MPM. Our results indicate
that the SRM assay technology lends itself for the fast
clinical evaluation of candidate biomarkers in serum. In
this respect, larger SRM-assays repositories are currently
being generated [64,65], which will ultimately enable the
quantitative evaluation of biomarker candidates of interest
in the disease setting of choice.
Methods
Cell culture
The MPM cell lines ZL55, SDM4, SDM5 and SDM34
were from surgical tumor samples and the pleural cell
line SDM104 was from a surgical biopsy of a patient
with chronic pleuritis. Cell lines were established as
previously described [66,67] and were from patients
with pathologically confirmed diagnosis and treated at
the University Hospital Zürich. HCC4012 was from
human mesothelial cells immortalized with hTERT
(kind gift of Dr. A. Gazdar, The University of Texas,
Southwestern Medical Center). ADCA cell lines Calu-3 and
SK-LU-1 were from American Type Culture Collection
(ATCC; Manassas, VA). Detailed growing conditions can
be found in Additional file 12: Supplementary Methods.
CSC-based surfaceome analysis and MPM candidate
biomarkers selection
CSC followed by MS analysis was performed as described
previously [30]. For label free relative-quantification,
raw data of duplicate measurements were acquired in
profile mode on a Fourier-Transform LTQ MS (FT-LTQ;
Thermo Electron, San Jose, CA), converted to mzXML
[68] and analyzed with the software Superhirn [69]. For
sequence identification MS/MS spectra of centroided raw
files were converted to mzXML and searched against the
IPI Human database v3.26 using the search algorithm
SEQUEST v27 [70]. Criteria for MPM candidate bio-
marker peptides were: 1. fully tryptic. 2. deamidation of
asparagine in the consensus sequence NxS/T (x denotes
any amino acid excluded proline) after treatment with
PNGaseF. 3. PeptideProphet probability ≥ 0.9. 4. sequence
proteotypic and unique for proteins reviewed in Uniprot
[71] and with subcellular localization associated to
membranes or secreted. 5. reproducibly higher abundant
in MPM in at least two MPM vs non-MPM cell lines
comparisons, or originating from the same protein of
an higher abundant peptide, or deriving from a protein
not observed in non-MPM cell lines but detected in MPM
at least in two cell lines or with two peptides. Further
details about quantitative CSC analysis are reported in
Additional file 12: Supplementary Methods.
Generation of SRM-assays
To establish glycopeptide-specific SRM assays, spectra
of MPM candidate biomarker glycopeptides were gen-
erated by using synthetic heavy isotope-labeled (heavy,
with R 13C6/
15 N4 and/or K
13C6/
15 N2) peptides (Spike-
Tides_L™, JPT Peptide Technologies, Berlin, Germany)
with aspartic acid (D) replacing the putative glycosylated
asparagines (N) according to the mass modification
introduced by treatment with the enzyme PNGaseF in
the protocol for enrichment of N-glycopeptides from
serum. Spectra were acquired on Quadrupole Time-of-
Flight (QTOF) LC/MS series 6520 or 6550 instruments
(Agilent Technologies, Santa Clara, CA) equipped with
an HPLC-Chip Cube interface (Agilent Technologies)
and operated in data dependent mode. MS/MS spectra
were used to generate initial SRM-assays for MPM
candidate biomarkers. They consisted of at least six
transitions per peptide selected based on signal inten-
sities of heavy peptides (SpikeTides_L™, JPT Peptide
Technologies) spiked in the matrix of enriched serum.
SRM-assays of candidate biomarkers detected in serum
were further individually optimized and consisted of four
transitions per peptide with at least three fixed transitions
used for quantification. Details about spectra acquisition,
MS settings, SRM-assays generation and optimization can
be found in Additional file 12: Supplementary Methods.
All assays developed can also be downloaded in form of a
Skyline library file (Additional file 5: Skyline file).
Serum samples
Whole blood samples were obtained after written
informed consent from therapy naïve patients with
pathologically proven diagnosis of MPM or NSCLC
and treated at the University Hospital Zürich. Staging
was based on TNM-International Union Against Can-
cer (UICC, sixth edition) selecting the highest stage in
case of ambiguous report. Whole blood samples from
HD were from blood donors at the Blood Transfusion
Service Zürich, SRC, Schlieren, Switzerland and judged
healthy based on standardized medical questionnaire
[72]. The study was approved by the Ethics Committee
of the University Hospital Zürich. Serum processing is
reported in Additional file 12: Supplementary Methods.
Serum enrichment for N-glycopeptides and MS analysis
For SRM analysis, 100 μl of serum were enriched for N-
glycopeptides using a modified protocol of the method
for solid phase extraction of N-glycopeptides (SPEG)
[21]. 1.5 μl of peptide mixture were analyzed on a QQQ
LC/MS 6460 series (Agilent Technologies) equipped with
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an HPLC-Chip Cube interface (Agilent technologies)
and using a nano-flow gradient of 5 to 35% acetonitrile
(ACN) /water, 0.1% formic acid (FA) over 30 min. The
software Skyline [73] was used for SRM-traces visual-
ization after Savitzky-Golay smoothing, SRM-methods
building and calculation of peak transition-intensities.
Details about serum processing and MS settings can be
found in Additional file 12: Supplementary Methods.
Verification of MPM candidate biomarker peptides
in serum
To verify the detectability of MPM candidate biomarker
peptides in serum, samples from five MPM subjects
were enriched for N-glycopeptides and analyzed on a
QQQ LC/MS instrument using not-optimized SRM-
assays. Sample processing and MS settings were as de-
scribed above. Transitions were monitored in scheduled
SRM-mode allowing for a maximum of 339 total transi-
tions and 176 concurrent transitions per method. Cycle-
times ranged from 2 to 4.1 s allowing for a minimal
dwell time of 18.5 ms per transition. Delta retention
time window was 4 or 5 min. Confident detection of
MPM candidate biomarker peptides in serum was manu-
ally confirmed based on transition co-elution with sim-
ultaneously monitored heavy isotope-labeled synthetic
peptides with matching sequences (SpikeTides_L™, JPT
Peptide Technologies) spiked in the samples before
MS analysis.
SRM analysis of candidate biomarker N-glycopeptides
from clinical cohorts
Serum samples of training and validation sets were
enriched for N-glycopeptides and analyzed using opti-
mized SRM assays on a QQQ LC/MS instrument as
described above. The two sets were processed and ana-
lyzed at separate time points. Samples of the same set
were processed simultaneously in randomized order and
analyzed in technical duplicates on the QQQ. Eleven
samples (normalizing-samples) from the training set
were re-processed and re-analyzed in parallel with the
validation set and results were used for normalization of
SRM signals between the two groups. These samples
were subsequently excluded from the validation set. For
relative quantification, a mix of heavy isotope-labeled
synthetic peptides with sequences matching the MPM
candidate biomarker peptides was used as internal
standard (SpikeTides_L™, JPT Peptide Technologies, for
mesothelin heavy isotope-labeled synthetic peptides were
from Thermo Scientific) and spiked at fixed concentration
in each sample before MS analysis at a volume ratio of 1:5
of heavy-peptide-mix to serum sample. To assess technical
variations among runs, iRT peptides (Biognosys, Schlieren,
Switzerland) [74] were spiked in each sample before MS
analysis. MS analysis of serum samples from the training
set was performed using a scheduled SRM method includ-
ing a total of 468 light and heavy transitions. Cycle time
was of 3.7 s allowing for the acquisition of at least eight
data points per peptide elution profile. RT window was
set to 5 min. Dwell time per transition ranged from a
minimum of 16 ms to a maximum of 459 ms. The
number of concurrent transitions ranged from 8 to
maximal 190. Samples of the validation set were ana-
lyzed in scheduled SRM-mode monitoring for a total of
288 light and heavy transitions. Cycle time was set to
3 s for the acquisition of at least eight data points per
peptide elution profile using a delta RT window of
5 min. Minimal dwell time per transition was 26.6 ms
and maximal was 459 ms. Minimal and maximal number
of concurrent transitions were 8 and 123 respectively.
Both method included transitions from the iRT peptides
and peptides of the serum proteins haptoglobin (UniProt
entry P00738) and kininogen-1 (UniProt entry P01042)
used as internal reference control for sample handling
and MS performance. Confident detection of MPM
candidate biomarker peptides was confirmed manually
based on transition co-elution with heavy isotope-labeled
internal standards.
Statistical significance analysis and prediction analysis
Statistical analysis of peptide differential abundance
utilized SRMstats package in R [37,75]. Ten peptides
of higher abundance in training set in either comparison
for MPM vs. HD or MPM vs. NSCLC were further used
in two logistic regression models for MPM vs HD and
MPM vs NSCLC. In order to account for relative experi-
mental yield and reproducibility of sample preparation
between training and validation sets, we developed a
two-step normalization procedure based on the eleven
normalizing-samples that were present in both sets.
The first normalization step accounted for variations in
the mass spectrometer performance, separately for the
training and the validation sets, by equating median
intensities of reference transitions between the runs. The
second normalization step shifted the intensities of the
endogenous transitions in the validation set to the scale
of the training set. Specifically, for each endogenous
transition we calculated the median difference of log-
intensities among the eleven normalizing-samples in
the validation and the training sets. The difference was
then subtracted from the endogenous intensities in all the
validation samples. All inputs for the logistic regressions
are estimates of peptide abundance in each biological sam-
ple on a relative scale, which are summarized across mul-
tiple transitions and technical replicate runs. This
summarization was performed in SRMstats fitting logistic
regression in R. ‘pROC’ package in R was used to draw
ROC curves and to calculate AUCs and CI with bootstrap
methods [76]. Correlations and Mann-Whithney test
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were calculated and visualized using IBM SPSS Statistics
Standard v17.0 (SPSS, Inc, Chicago, IL) or GraphPad
Prism 5 (GraphPad Software, Inc, San Diego, CA).
ELISA
Mesothelin ELISA in serum was performed in duplicates
using the Mesomark-kit™ (Fujirebio Diagnostic, Malvern,
PA) according to the manufacturer’s protocol. Averaged
values were used for analysis. Samples with coefficient of
variation > 15% were excluded.
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